[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336123-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336123-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","immune-related-serious-adverse-events-with-immune-checkpoint-inhibitors-systematic-review-and-network-meta-analysis","Immune-related serious adverse events with immune checkpoint inhibitors - Systematic review and network meta-analysis","","Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but uncertainty remains about their immune-related safety. This study compared the risk of immune-related serious adverse events (irSAEs) across ICIs and estimated absolute event rates in cancer patients. Randomized trials up to February 2021 were analyzed using Bayesian network meta-analysis, with overall irSAEs as the primary outcome and key toxicities as secondary outcomes. Results included 96 trials and showed distinct safety profiles across agents.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/immune-related-serious-adverse-events-with-immune-checkpoint-inhibitors-systematic-review-and-network-meta-analysis/336123/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/immune-related-serious-adverse-events-with-immune-checkpoint-inhibitors-systematic-review-and-network-meta-analysis/336123.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the main goal of this study?","Question",{"text":63,"@type":64},"To compare the safety profile of immune checkpoint inhibitors by assessing the odds of overall immune-related serious adverse events and estimating their absolute rates in cancer patients.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were irSAEs evaluated across treatments?",{"text":68,"@type":64},"The authors used Bayesian network meta-analyses of randomized trials up to February 2021, ranking treatments by SUCRA and estimating absolute event rates.",{"name":70,"@type":61,"acceptedAnswer":71},"Which ICIs showed the highest and lowest risk rankings in this analysis?",{"text":72,"@type":64},"Ipilimumab was the worst-ranked ICI, while atezolizumab was the best-ranked based on SUCRA and corresponding event rates reported in the results.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336123,1791396860,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":112,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":117,"preview_page_count":4},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","European Journal of Clinical Pharmacology (2024) 80:677–684  \n[https://doi.org/10.1007/s00228-024-03647-z](https://doi.org/10.1007/s00228-024-03647-z)  \nImmune‑related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta‑analysis  \nClara Oliveira1,2 · Beatrice Mainoli1,2,3 · Gonçalo S. Duarte1,2,4 · Tiago Machado1,2 · Rita G. Tinoco1,2,5 · Miguel Esperança‑Martins2,6 · Joaquim J. Ferreira1,2,7 · João Costa1,2,8  \nReceived: 26 October 2023 / Accepted: 3 February 2024 / Published online: 19 February 2024 © The Author(s) 2024, corrected publication 2024  \nAbstract  \nPurpose Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, though uncertainty exists regarding their immune-related safety. The objective of this study was to assess the comparative safety profile (odds ratio) of ICIs and estimate the absolute rate of immune-related serious adverse events (irSAEs) in cancer patients undergoing treatment with ICIs. Methods We searched for randomized trials till February 2021, including all ICIs for all cancers. Primary outcome was overall irSAEs, and secondary outcomes were pneumonitis, colitis, hepatitis, hypophysitis, myocarditis, nephritis, and pancreatitis. We conducted Bayesian network meta-analyses, estimated absolute rates and ranked treatments according to the surface under the cumulative ranking curve (SUCRA) .  \nResults We included 96 trials (52,811 participants, median age 62 years) . Risk of bias was high in most trials. Most cancers were non-small cell lung cancer (28 trials) and melanoma (15 trials). The worst-ranked ICI was ipilimumab (SUCRA 14%; event rate 848/10,000 patients) while the best-ranked ICI was atezolizumab (SUCRA 82%; event rate 119/10,000 patients) . Conclusion Each ICI showed a unique safety profile, with certain events more frequently observed with specific ICIs, which should be considered when managing cancer patients.  \nKeywords Systematic review · Network meta-analysis · Clinical trials · Immune check-point inhibitors · Cancer · Safety  \n* João Costa [jcosta.fml@gmail.com](jcosta.fml@gmail.com)  \n1 Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028 Lisbon, Portugal  \n2 Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal  \n3 Clinical Research Unit, Research Center of IPO Porto (CI-IPOP)/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)/Porto Comprehensive Cancer Center (Porto.CCC), Porto, Portugal  \n4 Clinical Pharmacology Department, Hospital da Luz Lisboa, Lisbon, Portugal  \n5 Departamento Médico Grunenthal, SA, Lisbon, Portugal  \n6 Department of Medical Oncology, Centro Hospitalar Universitário Lisboa Norte, Hospital Santa Maria, Lisbon, Portugal  \n7 7CNS–Campus Neurológico Sénior, Torres Vedras, Portugal  \n8 Centro de Estudos de Medicina Baseada na Evidência, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal  \nIntroduction  \nImmune checkpoint inhibitors (ICIs) have revolutionized the treatment of a vast array of cancers, both in a curative and palliative context [1, 2] . Their current use has focused on anti-CTLA-4 antibodies (ipilimumab, tremelimumab), antiPD-1 agents (pembrolizumab, nivolumab, cemiplimab), and anti-PD-L1 agents (atezolizumab, avelumab, durvalumab) . By blocking intrinsic immunity downregulators, ICIs increase antitumor immunity [3] increasing T cell activation and proliferation, reducing Treg functions, and possibly boosting humoral autoimmunity [4] .  \nAlthough commonalities exist between the toxicity profiles of different ICIs, there are important differences in the frequency and presentation of specific immune-related adverse events (irAEs) [5] . These events occur via T cell activation and cross-reactivity between antitumor T cells and similar antigens on healthy cells, increased cytokine secretion, autoantibody e","cbCaiuyk9an91OF8","https://ap.wps.com/l/cbCaiuyk9an91OF8","pdf",906610,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Mechanisms and toxicity differences\n## Prior evidence and study rationale\n# Methods\n## Eligibility criteria\n## Search and selection","[{\"question\":\"What was the main goal of this study?\",\"answer\":\"To compare the safety profile of immune checkpoint inhibitors by assessing the odds of overall immune-related serious adverse events and estimating their absolute rates in cancer patients.\"},{\"question\":\"How were irSAEs evaluated across treatments?\",\"answer\":\"The authors used Bayesian network meta-analyses of randomized trials up to February 2021, ranking treatments by SUCRA and estimating absolute event rates.\"},{\"question\":\"Which ICIs showed the highest and lowest risk rankings in this analysis?\",\"answer\":\"Ipilimumab was the worst-ranked ICI, while atezolizumab was the best-ranked based on SUCRA and corresponding event rates reported in the results.\"}]","Immune-related serious adverse events with immune checkpoint inhibitors - Systematic review and network meta-analysis | PDF",1790013664]